The determinants of therapeutic observance in open-angle glaucoma

##plugins.themes.academic_pro.article.sidebar##

Published Sep 7, 2018
Download
pdf
Vol. 96 No. 6 (2018): Issue Jun 2018

##plugins.themes.academic_pro.article.main##

Fatma Amar
Fatma Amara
Hager Ben Amor
Imene Kaibi
Mariem Taktak
Jalel Taktak

Abstract

Adherence to medical treatment in primary open angle glaucoma is key to the success of the treatment. Most of the work show that glaucoma patients are poor observant. Poor adherence is multifactorial. The analysis of these factors is crucial. That is why the author wanted to expose, through a literature review, the main determinants of adherence in glaucoma.

Keywords:

glaucoma, determinants, compliance, treatment, blindness.

##plugins.themes.academic_pro.article.details##

References

  1. Dasgupta S., Oates V., Bookhart B.K., Vaziri B., Schwartz G.F., Mozaffari E.Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8:255-61.
  2. Friedman D.S., Quigley H.A., Gelb L., Tan J., Margolis J., Shah S.N., et al.Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052-7.
  3. Nordstrom B.L., Friedman D.S., Mozaffari E., Quigley H.A., Walker A.M.Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
  4. Naacke H., Baudoin C.Le patient glaucomateux et son traitement : qu'en est-il réellement?J.Fr. Ophtalmol. 1999;22:99-101.
  5. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
  6. Newman-Casey P, Weizer J, Heisler M, Lee P, Stein JD.Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence. SeminOphthalmol. 2013;28(3):191-201.
  7. Nordmann J-P., Akesbi J. Améliorer l'adhérence au traitement des patients glaucomateux : le rôle du médecin.J. Fr. Ophtalmol. 2011;34(6):403-8.
  8. Chambonet J-Y, Brouard F.Oubliez-vous vos médicaments?Concours med 2001;123:2159-63.
  9. Wane A.M., Ndiaye M.R., Wade A., Ndiaye P.A.L'observance au traitement médical dans le glaucome primitif à angle ouvert. Résultats préliminaires. J.Fr. Ophtalmol. 2003;26:1039-44.
  10. Bron, A., Nordmann J-P, Baudoin C, Rouland F, KadiA, Sartral M.Glaucome et hypertonie oculaire: importance de la pression intra oculaire cible dans la prise en charge thérapeutique en France.J.Fr. Ophtalmol. 2003;26:895-903.
  11. Tsai J.C., McClure C.A., Ramos S.E., Schlundt D.G., Pichert J.W. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003. 12 : 393-8.
  12. Tsai J.C. A comprehensive perspective on patient adherence to topical glaucoma therapy.Ophthalmology. 2009;116:S30-S36.
  13. Bour T. Blanchard F., Segal A.Données épidémiologiques sur le glaucome primitif à angle ouvert et son traitement dans la Marne.J.Fr. Ophtalmol. 1993;16:367-79.
  14. Friedman D.S, Okeke C.O, Jampel H.D., Ying G.S., Plyler R.J., Jiang Y., et al.Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009; 116:1097-105.
  15. Gurwitz J.H, Glynn R.J, Monane M, Everitt DE, Gilden D, Smith N, et al.Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993;83:711-6.
  16. Renard J.P, Giraud J.M, Fenolland J.R, F. May.L'adhérence au traitement dans le glaucome. J. Fr. Ophtalmol. 2010;33(4):291-5.
  17. Van Went C, Brasnu E, Hamard P, Baudouin C, LabbéA.Influence des pathologies de la surface oculaire sur le traitement du glaucomeJ. Fr. Ophtalmol. 2011;34(4):230-7.
  18. Hamelin N., Blatrix C., Brion F, C. Mathieu, I. Goemaere, J.-P. Nordmann.Comment les patients réagissent-ils à la découverte d'un glaucome?J.Fr.Ophtalmol. 2002;25:795-98.
  19. Schwed Girardin A., Darioli R.La compliance thérapeutique et ses déterminants. Méd et Hyg 1994;52:557-60.
  20. Demailly Ph., Zoute C., Castro D.Personnalités et glaucome chronique.J.Fr.Ophtalmol. 1989;12:595-601.
  21. Kashiwagi K, Tsukahara S. Impact of Patient Access to Internet Health Records on Glaucoma Medication: Randomized Controlled Trial. J Med Internet Res. 2014;16(1): e15
  22. Leung VC, Jin YP, Hatch W, Mammo Z, Trope GE, Buys YM et al.The relationship between sociodemographic factors and persistence with topical glaucoma medications. J Glaucoma. 2015;24(1):69-76.
  23. Chan CH, Trope GE, Badley EM, Buys YM, Jin YP. The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss. Invest Ophthalmol Vis Sci. 2014;9;55(12):8544-9.
  24. Schwartz G.F. Compliance and persistency in glaucoma follow up treatment. Curr. Opin. Ophthalmol. 2005;16:114-21.
  25. Diestelhorst M., Schaefer C.P., Beusterien K.M., Plante K.M., Fain J.M., Mozaffari E., et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: Evidence from a European retrospective cohort study. Eur J Ophthalmol. 2003;13(Suppl. 4):21-9.
  26. WilenskyJ., Fiscella R.G., Carlson A.M., Morris L.S., Walt J.Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141:28-33.
  27. Robin A.L., Novack G.D., Covert D.W., Crockett R.S., Marcic T.S.Adherence in glaucoma: objective measurements of once daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-40.
  28. Djafari F., Lesk M.R., Harasymowicz P.J., Desjardins D., Lachaine J.Determinants of adherence to glaucoma medical therapy in a long term patient population. J Glaucoma. 2009; 18:238-42.